Skip to content

Study · Animal study (in vivo) · 2020

4 results

Hindbrain melanocortin 3/4 receptors modulate the food intake and body weight suppressive effects of the GLP-1 receptor agonist, liraglutide.

Fortin SM, Chen J, Hayes MR

Physiology & behavior14 Mar 2020Cited by 7 (Europe PMC)

PMID32179053 (opens in a new tab)PMCIDPMC7227776 (opens in a new tab)DOI10.1016/j.physbeh.2020.112870 (opens in a new tab)PepBankPUB-32179053
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

1 result from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Mechanism

    In animals, melanotan II given in the DVC together with liraglutide enhanced the anorectic effects of liraglutide.

    In plain wordsIn animals, melanotan II given in the hindbrain together with liraglutide made the appetite-reducing effect stronger.

    Peptide
    Melanotan II
    Outcome
    IncreaseAnorectic effect of liraglutide enhanced by DVC melanotan II
    Study

    n: not reported in source

    Dorsal vagal complex (DVC) drug administration
    Outcome group
    Appetite and food intake · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    In contrast, the anorectic effects of liraglutide were enhanced by combined activation of DVC MC3/4Rs using the agonist MTII.

Studies that did not test the peptide alone3

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 02AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Mechanism

    In animals, DVC administration of the MC3/4R antagonist SHU9119 attenuated the food intake suppression by liraglutide.

    In plain wordsIn animals, blocking melanocortin receptors in the hindbrain weakened the food-reducing effect of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseLiraglutide food intake suppression with DVC SHU9119
    Study

    n: not reported in source

    Dorsal vagal complex (DVC) drug administration
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    Specifically, the food intake and body weight suppressive effects of liraglutide were attenuated by DVC administration of the MC3/4R antagonist SHU9119.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 03AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Mechanism

    In animals, DVC administration of the MC3/4R antagonist SHU9119 attenuated the body weight suppression by liraglutide.

    In plain wordsIn animals, blocking melanocortin receptors in the hindbrain weakened the weight-reducing effect of liraglutide.

    Peptide
    Liraglutide
    Outcome
    DecreaseLiraglutide body weight suppression with DVC SHU9119
    Study

    n: not reported in source

    Dorsal vagal complex (DVC) drug administration
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    Specifically, the food intake and body weight suppressive effects of liraglutide were attenuated by DVC administration of the MC3/4R antagonist SHU9119.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  3. 04AnimalNot a test of Liraglutide aloneAnimal study (in vivo)Mechanism

    In animals, combined DVC activation of MC3/4Rs with MTII enhanced the anorectic effects of liraglutide.

    In plain wordsIn animals, adding a melanocortin receptor activator in the hindbrain made the appetite-reducing effect of liraglutide stronger.

    Peptide
    Liraglutide
    Outcome
    IncreaseLiraglutide anorectic effect with DVC MTII
    Study

    n: not reported in source

    Dorsal vagal complex (DVC) drug administration
    Outcome group
    Appetite and food intake · Metabolic and weight

    Source sentences

    Summary
    In contrast, the anorectic effects of liraglutide were enhanced by combined activation of DVC MC3/4Rs using the agonist MTII.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:05 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.